Aurora Advanced Flow Cytometry System from Cytek Biosciences Continues to Gain Traction
Patented, Unique, Differentiated Solution Embraced by Researchers around the Globe
FREMONT, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- First introduced in June of last year, the Aurora advanced flow cytometry system from Cytek Biosciences Inc. has gained significant traction in the scientific community - and is setting the new standard for what is possible. Aurora has now been sold into four continents - Asia, North America, Australia, and Europe. Cytek's mission is to fill a gap in the industry by making high-dimensional flow cytometry accessible to a larger number of researchers - and the company has its sights set on the remaining three continents.
Its superb performance has enabled the possibility of new discoveries and deeper biological insights at an affordable cost. Unlike other spectral flow cytometers, Aurora is a full spectrum flow cytometer based on Cytek's innovative architecture that does not use any optical dispersive element in its fluorescence detection system. The use of multiple excitation lasers enable Aurora's collection optics system to cover the entire luminescence emission window - from ultraviolet to infrared. By employing solid state detector arrays as opposed to conventional PMT detectors, Aurora is able to be packaged in a compact platform with excellent sensitivity. This enhanced sensitivity allows for the co-labeling of cells using dyes with highly overlapping spectral profiles and the resolution of dim and rare populations. More than 20-color labels are achievable with only three onboard lasers at 405 nm, 488 nm and 640 nm. This Cytek innovative technology is covered by pending patent applications, the most recent of which published on January 25, 2018.
Reflecting on the state of flow cytometry today, Dr. Wenbin Jiang, CEO of Cytek Biosciences, noted that, "Traditionally, the flow cytometry industry has been monopolized by a few large players with little motivation to innovate. Most flow cytometers on the market are based on 20-year-old technology that fails to meet today's application requirements. For example, applications in the field of immuno-oncology require the use of many colors from a single sample. Conventional flow cytometer designs try to meet this requirement by merely adding excitation laser wavelengths in the infrared and ultraviolet, which significantly increased the cost of ownership and complicated maintenance and usage. If you look at the telecom industry as a counterpoint, it is quickly apparent that - after the demise of the old monopoly - innovation has flourished, leading to today's IT and cloud services that have positively impacted lives the world over." Dr. Jiang, himself a veteran of the telecom industry, is an inventor who holds close to 100 U.S. patents.
Under the leadership of Dr. Jiang, Cytek has meshed innovative telecom technology with its 25 years of experiences in flow cytometer advancement, leading to the all-new full spectrum flow cytometer, Aurora. "Aurora has now been sold into four continents and has leapfrogged competing solutions to satisfy long unmet needs in fields of research such as immuno-oncology, systems biology, extracellular vesicles, stem cells and genomics," continued Dr. Jiang. "We hear from our customers that other solutions have fallen well short of their expectations, and that Aurora is the cytometer that they have been waiting for."
Please visit www.cytekbio.com for more information on Aurora and to learn more about Cytek's lineup of flow cytometry solutions, all of which are backed by comprehensive service plan offerings.
About Cytek Biosciences
Cytek is a leading flow cytometry solution provider and provides compact, affordable instruments with high multiplexing capability and a wide range of services to support researchers and clinicians. Cytek Biosciences Inc. is the outcome of a merger between Cytek Development Inc., a leading pioneer in flow cytometry, and Cytoville Inc., a venture-capital-backed business focusing on advanced bio-medical instrument technology development. The company's headquarters are in Fremont, California with branch offices and distribution channels across the globe. To learn more, visit www.cytekbio.comand follow them on LinkedIn.
Lages & Associates
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cytek Biosciences via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Platinum Equity to Sell Worldwide Flight Services for €1.2 Billion19.6.2018 15:00 | Pressmeddelande
Successful investment adds to Platinum Equity's continued momentum in Europe LOS ANGELES, June 19, 2018 (GLOBE NEWSWIRE) -- Platinum Equity today announced it has signed a definitive agreement to sell Worldwide Flight Services (WFS) to affiliates of Cerberus Capital Management, L.P. in a transaction valued at approximately €1.2 billion. The sale is expected to close during Q4 2018, subject to regulatory approval and certain closing conditions. Since Platinum Equity acquired the company in 2015, WFS has grown significantly, both organically and through a transformative add-on acquisition, and is now the world's largest air cargo handler and one of the world's leading providers of ground handling and technical services, with annual revenues of more than €1.2 billion. "Through a combination of growth and operational initiatives, WFS has evolved and expanded significantly over the past three years and today enjoys record top-line and earnings performance," said Platinum Equity Partner Loui
CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents19.6.2018 14:00 | Pressmeddelande
SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline. CrownBio boasts the world's largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre's innovative immuno-oncology drug discovery pipeline. "Pierre Fabre recognizes the value of CrownBio's extensive PDX collection and their expertise in implementing innovative humanization strategies," said Nathalie Corvaia, P
Quantenna's New QSR10GU-AX Plus Raises the Bar for Wi-Fi Performance and Functionality19.6.2018 14:00 | Pressmeddelande
SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ:QTNA), the innovator and global leader of high performance Wi-Fi solutions, today announced that the QSR10GU-AX Plus, a new enhanced solution targeting gateways and access points based on the draft IEEE 802.11ax standard, is now sampling to select customers. Building upon Quantenna's pioneering QSR10G-AX Wi-Fi platform, QSR10GU-AX Plus offers unique capabilities, including Adaptive 5 GHz, SuperTx and ESP, providing significant performance gains across a variety of home configurations. The QSR10GU-AX Plus can operate concurrently in both 8x8 MIMO in the 5 GHz band and 4x4 MIMO in the 2.4 GHz band supporting a total of 12 streams. Unique features of QSR10GU-AX Plus include: Dynamic switching between 8x8 MIMO and dual 4x4 MIMO in the 5 GHz band by applying adaptive algorithms, enabled by Quantenna's unique baseband and RF architecture design. This provides the end users with the best possible MIMO c
Glatfelter to Acquire Georgia-Pacific's European Nonwovens Business for $185 Million19.6.2018 13:44 | Pressmeddelande
YORK, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- June 19, 2018 - Glatfelter (NYSE:GLT), a global supplier of specialty papers and engineered materials, today announced it has signed a definitive agreement to purchase Georgia-Pacific's European nonwovens business (the "Business") for $185 million, subject to customary purchase price adjustments. The proposed transaction includes Georgia-Pacific's operations located in Steinfurt, Germany, along with sales offices located in France and Italy. The Steinfurt facility produces high-quality airlaid products for the table-top, wipes, hygiene, food pad, and other nonwoven materials markets, competing in the marketplace with nonwoven technologies and substrates, as well as other materials focused primarily on consumer based end-use applications. The Steinfurt facility is a state-of-the-art, 32,000-metric-ton-capacity manufacturing facility that employs approximately 220 people. "Glatfelter's agreement to acquire the European nonwovens business demon
Industry stakeholders partner on blockchain based margin and collateral solution19.6.2018 13:00 | Pressmeddelande
AMSTERDAM, the Netherlands, BRUSSELS, Belgium, LONDON and STOCKHOLM, Sweden, June 19, 2018 (GLOBE NEWSWIRE) -- ABN AMRO Clearing, EuroCCP, Euroclear and Nasdaq have completed a joint proof of concept to make the use of securities more efficient when used to cover margin calls, including after business hours, using blockchain, or distributed ledger technology (DLT). This solution addresses significant business challenges and inefficiencies related to the current provision of collateral to Central Counterparties (CCPs) and has demonstrated that a shared, resilient network can be built between collateral givers, collateral takers and intermediaries. The inefficiencies of collateral processing have been heightened as a result of recent market changes such as extended trading hours by stock exchanges and the requirement to centrally clear derivatives traded bilaterally (OTC) under the European Market Infrastructure Regulation (EMIR). Today, a CCP margin call typically needs to be covered by
Lithium Werks and Endrich agree pan-Asian battery distribution deal19.6.2018 09:00 | Pressmeddelande
AUSTIN, Texas, June 19, 2018 (GLOBE NEWSWIRE) -- Battery and portable power solutions group Lithium Werks B.V. has signed a strategic distribution agreement with Taipei, Taiwan-based distributor Endrich Co., Ltd to bolster its support for Asian customers. "Demand for lithium batteries from Asian customers has been strong for a long time, but even so, we've seen nothing yet. We expect an enormous uptick in demand in the years ahead," said T. Joseph Fisher III, CEO and co-founder of Lithium Werks. "With its unrivaled knowledge of Asian markets, Endrich is a trusted supplier to a number of tier-one ODMs (original design manufacturers) and OEMs (original equipment manufacturers). "Together, we will continue to develop ever closer relationships with customers in markets such as Taiwan, Japan, South Korea and, not least, China, where we are preparing to build a lithium battery giga factory," he said. "I have known Endrich for a long time, so I already know that this partnership will be benef
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum